357 |
A Critical Appraisal of Percutaneous Aortic Valve Therapies: Device Concepts, Clinical Outcomes, and Future Projections |
Martin Bert Leon |
May. 18. 07 |
356 |
IVUS Findings in DES Thrombosis |
Gary S. Mintz |
May. 18. 07 |
355 |
Renal Failure and Contrast Nephropathy: An Overview and Considerations in the PCI Patient |
Roxana Mehran |
May. 18. 07 |
354 |
Is There a Safety Advantage in the PC Based DES Systems? Possible Mechanisms |
Alan C. Yeung |
May. 18. 07 |
353 |
The Baseline Clinical Features and Plaque Characteristics from the PROSPECT Trial |
Gregg W. Stone |
May. 18. 07 |
352 |
Virtual Histology-Clinical Application, Insights into Future Use |
Barry D. Rutherford |
May. 18. 07 |
351 |
New DES Drug Carrier Systems: Biostable, Bioabsorbable, and No Polymers, Elution Kinetics, and Beyond! |
Martin Bert Leon |
May. 11. 07 |
350 |
Predictors of DES Restenosis: Results from a Large Database |
Adnan Kastrati |
May. 11. 07 |
349 |
Predictors of Late DES Thrombosis and Reflections on Dual Antiplatelet Therapy |
Alexandre Abizaid |
May. 11. 07 |
348 |
Should DES Use be Reduced Due to Safety Concerns? Important Messages from the Randomized DES Trials |
Gregg W. Stone |
May. 11. 07 |